Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-20
DOI
10.1038/s41375-021-01261-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
- (2020) Haifa Kathrin Al‐Ali et al. BRITISH JOURNAL OF HAEMATOLOGY
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
- (2020) Vikas Gupta et al. LEUKEMIA & LYMPHOMA
- Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Donal McLornan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
- (2019) Prithviraj Bose Expert Opinion on Orphan Drugs
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
- (2018) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments
- (2017) Ayalew Tefferi Blood Cancer Journal
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
- (2017) Francesca Palandri et al. Oncotarget
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
- (2016) Haifa Kathrin Al-Ali et al. LEUKEMIA & LYMPHOMA
- Alleviating anemia and thrombocytopenia in myelofibrosis patients
- (2016) Francisco Cervantes et al. Expert Review of Hematology
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
- (2015) Adam J. Mead et al. BRITISH JOURNAL OF HAEMATOLOGY
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Practical management of patients with myelofibrosis receiving ruxolitinib
- (2013) Claire Harrison et al. Expert Review of Hematology
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
- (2008) Omar I. Abdel-Wahab et al. Annual Review of Medicine
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started